Calcineurin Inhibitor Withdrawal After Renal Transplantation with Alemtuzumab: Clinical Outcomes and Effect on T-Regulatory Cells
Authors:
Open Access
- 1 July 2008
- journal article
- research article
- Published by Elsevier in American Journal of Transplantation
- Vol. 8 (7) , 1529-1536
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Banff ’05 Meeting Report: Differential Diagnosis of Chronic Allograft Injury and Elimination of Chronic Allograft Nephropathy (’CAN’)American Journal of Transplantation, 2007
- The evolving role of alemtuzumab (Campath-1H) for immunosuppressive therapy in organ transplantationTransplant International, 2006
- Living Donor Renal Transplantation Using Alemtuzumab Induction and Tacrolimus MonotherapyAmerican Journal of Transplantation, 2006
- Inhibition of CD4+CD25+ regulatory T-cell function by calcineurin-dependent interleukin-2 productionBlood, 2006
- A function for interleukin 2 in Foxp3-expressing regulatory T cellsNature Immunology, 2005
- Predictive Factors of Acute Rejection after Early Cyclosporine Withdrawal in Renal Transplant Recipients Who Receive Mycophenolate MofetilJournal of the American Society of Nephrology, 2005
- Alemtuzumab Induction and Prednisone‐Free Maintenance Immunotherapy in Kidney Transplantation: Comparison with Basiliximab Induction—Long‐Term ResultsAmerican Journal of Transplantation, 2005
- Withdrawal of Cyclosporine or Prednisone Six Months after Kidney Transplantation in Patients on Triple Drug Therapy: A Randomized, Prospective, Multicenter StudyJournal of the American Society of Nephrology, 2002
- The Banff 97 working classification of renal allograft pathologyKidney International, 1999
- PREDICTING GLOMERULAR FILTRATION RATE AFTER KIDNEY TRANSPLANTATIONTransplantation, 1995